Biotech | October 28, 2021
MSD and MPP sign licensing agreement to make molnupiravir affordable
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
The list of kids with co-morbidities eligible for vaccination would be announced by the government
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
It is the first presbyopia-correcting lens implant for cataract surgery
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
U.S. FDA to decide whether to authorize a booster dose in the coming days
Subscribe To Our Newsletter & Stay Updated
